<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35690735</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>216</StartPage><MedlinePgn>216</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">216</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02730-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable and rapidly progressive neurological disorder. Biomarkers are critical to understanding disease causation, monitoring disease progression and assessing the efficacy of treatments. However, robust peripheral biomarkers are yet to be identified. Neuroinflammation and breakdown of the blood-brain barrier (BBB) are common to familial and sporadic ALS and may produce a unique biomarker signature in peripheral blood. Using cytometric bead array (n&#x2009;=&#x2009;15 participants per group (ALS or control)) and proteome profiling (n&#x2009;=&#x2009;6 participants per group (ALS or control)), we assessed a total of 106 serum cytokines, growth factors, and BBB breakdown markers in the serum of control and ALS participants. Further, primary human brain pericytes, which maintain the BBB, were used as a biosensor of inflammation following pre-treatment with ALS serum. Principal components analysis of all proteome profile data showed no clustering of control or ALS sera, and no individual serum proteins met the threshold for statistical difference between ALS and controls (adjusted P values). However, the 20 most changed proteins between control and ALS sera showed a medium effect size (Cohen's d&#x2009;=&#x2009;0.67) and cluster analysis of their levels together identified three sample subsets; control-only, mixed control-ALS, and ALS-only. These 20 proteins were predominantly pro-angiogenic and growth factors, including fractalkine, BDNF, EGF, PDGF, Dkk-1, MIF and angiopoietin-2. S100&#x3b2;, a protein highly concentrated in glial cells and therefore a marker of BBB leakage when found in blood, was unchanged in ALS serum, suggesting that serum protein profiles were reflective of peripheral rather than CNS biofluids. Finally, primary human brain pericytes remained proliferative and their secretome was unchanged by chronic exposure to ALS serum. Our exploratory study suggests that individual serum cytokine levels may not be robust biomarkers in small studies of ALS, but that larger studies using multiplexed analysis of pro-angiogenic and growth factors may identify a peripheral signature of ALS pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Maize C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cawston</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, Massey University, PO Box 75, Wellington, 6140, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Collin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, Massey University, PO Box 75, Wellington, 6140, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douwes</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, Massey University, PO Box 75, Wellington, 6140, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Dave</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, Massey University, PO Box 75, Wellington, 6140, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>E Scott</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine and Pathology, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragunow</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand. m.dragunow@auckland.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. m.dragunow@auckland.ac.nz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scotter</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacology, University of Auckland, 85 Park Road, Auckland, 1023, New Zealand. emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. emma.scotter@auckland.ac.nz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Blood-brain barrier</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Serum</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>11</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35690735</ArticleId><ArticleId IdType="pmc">PMC9188104</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02730-1</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02730-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, et al. Time to diagnosis in the National Registry of veterans with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):125&#x2013;132. doi: 10.3109/17482960802572681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802572681</ArticleId><ArticleId IdType="pubmed">19153849</ArticleId></ArticleIdList></Reference><Reference><Citation>Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014;343(1&#x2013;2):173&#x2013;175. doi: 10.1016/j.jns.2014.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.06.003</ArticleId><ArticleId IdType="pubmed">24972820</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):136&#x2013;143. doi: 10.1080/14660820310011250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310011250</ArticleId><ArticleId IdType="pubmed">13129799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7(6):557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3&#x2013;S9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, et al. Humoral factors in ALS patients during disease progression. J Neuroinflammation. 2015;12:127. doi: 10.1186/s12974-015-0350-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Moller T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport. 2005;16(6):527&#x2013;531. doi: 10.1097/00001756-200504250-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200504250-00001</ArticleId><ArticleId IdType="pubmed">15812300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J NeuroImmune Pharmacol. 2013;8(4):888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10(3):253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol. 2009;210(1&#x2013;2):73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11(3):246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Geranmayeh MH, Rahbarghazi R, Farhoudi M. Targeting pericytes for neurovascular regeneration. Cell Commun Signal. 2019;17(1):26. doi: 10.1186/s12964-019-0340-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-019-0340-8</ArticleId><ArticleId IdType="pmc">PMC6425710</ArticleId><ArticleId IdType="pubmed">30894190</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562&#x2013;566. doi: 10.1038/nature09513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09513</ArticleId><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Bell RD, Wang J, Zlokovic BV. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab. 2012;32(10):1841&#x2013;1852. doi: 10.1038/jcbfm.2012.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.113</ArticleId><ArticleId IdType="pmc">PMC3463878</ArticleId><ArticleId IdType="pubmed">22850407</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557&#x2013;561. doi: 10.1038/nature09522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09522</ArticleId><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro R, Compte M, Alvarez-Vallina L, Sanz L. Immune regulation by Pericytes: modulating innate and adaptive immunity. Front Immunol. 2016;7:480. doi: 10.3389/fimmu.2016.00480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00480</ArticleId><ArticleId IdType="pmc">PMC5095456</ArticleId><ArticleId IdType="pubmed">27867386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansson D, Rustenhoven J, Feng S, Hurley D, Oldfield RL, Bergin PS, et al. A role for human brain pericytes in neuroinflammation. J Neuroinflammation. 2014;11:104. doi: 10.1186/1742-2094-11-104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-104</ArticleId><ArticleId IdType="pmc">PMC4105169</ArticleId><ArticleId IdType="pubmed">24920309</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66(6):852&#x2013;856. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolski S, Nikolic J, Bugarski-Prokopljevic C, Miletic V, Pavlovic S, Filipovic S. Serum and CSF immunological findings in ALS. Acta Neurol Scand. 1991;83(2):96&#x2013;98. doi: 10.1111/j.1600-0404.1991.tb04656.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1991.tb04656.x</ArticleId><ArticleId IdType="pubmed">2017904</ArticleId></ArticleIdList></Reference><Reference><Citation>Annunziata P, Volpi N. High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol Scand. 1985;72(1):61&#x2013;64. doi: 10.1111/j.1600-0404.1985.tb01548.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1985.tb01548.x</ArticleId><ArticleId IdType="pubmed">4050318</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters S, Swanson MEV, Dieriks BV, Zhang YB, Grimsey NL, Murray HC, Turner C, Waldvogel HJ, Faull RLM, An J, Bowser R, Curtis MA, Dragunow M, Scotter E. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS. Acta Neuropathol Commun. 2021;9(1):144. 10.1186/s40478-021-01244-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393479</ArticleId><ArticleId IdType="pubmed">34446086</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol. 1984;6(1):51&#x2013;57. doi: 10.1016/0165-5728(84)90042-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(84)90042-0</ArticleId><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MC, Haller E, Frisina-Deyo A, Mirtyl S, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114&#x2013;128. doi: 10.1016/j.brainres.2012.05.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan RF, Guo Y. Toxic effect of hemoglobin on spinal cord neurons in culture. J Neurotrauma. 1998;15(8):645&#x2013;653. doi: 10.1089/neu.1998.15.645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1998.15.645</ArticleId><ArticleId IdType="pubmed">9726263</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti-Fabregas J, Soler R, Esquerda J, Grau JM, Pradas J, Illa I. Clinical status of motoneuron disease does not correlate with serum neurotoxicity on cultured neurons. Acta Neurol Scand. 1992;85(3):219&#x2013;223. doi: 10.1111/j.1600-0404.1992.tb04032.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1992.tb04032.x</ArticleId><ArticleId IdType="pubmed">1575008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, et al. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(5):283&#x2013;287. doi: 10.1080/17482960701419232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701419232</ArticleId><ArticleId IdType="pubmed">17852013</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos A, et al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand. 2010;122(6):425&#x2013;429. doi: 10.1111/j.1600-0404.2010.01333.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2010.01333.x</ArticleId><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2000;287(3):211&#x2013;214. doi: 10.1016/S0304-3940(00)01177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01177-0</ArticleId><ArticleId IdType="pubmed">10863032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, Baiocchi C, Bongioanni P, Cova E, Guareschi S, Metelli MR, et al. TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol. 2008;194(1&#x2013;2):123&#x2013;131. doi: 10.1016/j.jneuroim.2007.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.028</ArticleId><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Houi K, Kobayashi T, Kato S, Mochio S, Inoue K. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002;106(5):299&#x2013;301. doi: 10.1034/j.1600-0404.2002.01301.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2002.01301.x</ArticleId><ArticleId IdType="pubmed">12371924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol Sci. 2001;187(1&#x2013;2):27&#x2013;34. doi: 10.1016/S0022-510X(01)00514-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00514-7</ArticleId><ArticleId IdType="pubmed">11440741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth LCD, Rustenhoven J, Park TI, Schweder P, Jansson D, Heppner PA, et al. Unique and shared inflammatory profiles of human brain endothelia and pericytes. J Neuroinflammation. 2018;15(1):138. doi: 10.1186/s12974-018-1167-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1167-8</ArticleId><ArticleId IdType="pmc">PMC5948925</ArticleId><ArticleId IdType="pubmed">29751771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, Scotter EL, Jansson D, Kho DT, Oldfield RL, Bergin PS, et al. An anti-inflammatory role for C/EBPdelta in human brain pericytes. Sci Rep. 2015;5:12132. doi: 10.1038/srep12132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12132</ArticleId><ArticleId IdType="pmc">PMC4499812</ArticleId><ArticleId IdType="pubmed">26166618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GX, 't Mannetje AM, Douwes J, van den Berg L, Pearce N, Kromhout H, et al. Occupation and motor neuron disease: a New Zealand case-control study. Occup Environ Med. 2019;76(5):309&#x2013;316. doi: 10.1136/oemed-2018-105605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/oemed-2018-105605</ArticleId><ArticleId IdType="pubmed">30902826</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons HM, Hughes SM, Van Roon-Mom W, Greenwood JM, Narayan PJ, Teoh HH, et al. Cellular composition of human glial cultures from adult biopsy brain tissue. J Neurosci Methods. 2007;166(1):89&#x2013;98. doi: 10.1016/j.jneumeth.2007.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2007.07.005</ArticleId><ArticleId IdType="pubmed">17719090</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, Jansson D, Smyth LC, Dragunow M. Brain Pericytes as mediators of Neuroinflammation. Trends Pharmacol Sci. 2017;38(3):291&#x2013;304. doi: 10.1016/j.tips.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2016.12.001</ArticleId><ArticleId IdType="pubmed">28017362</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuche W, Yushchenko M, M&#xe4;der M, Maliszewska M, Felgenhauer K, Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000;11(16):3419&#x2013;3422. doi: 10.1097/00001756-200011090-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200011090-00003</ArticleId><ArticleId IdType="pubmed">11095490</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Gosset P, Brunaud-Danel V, Tonnel AB, Lassalle P, et al. Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: a clinical study. Rev Neurol-France. 2010;166(3):279&#x2013;283. doi: 10.1016/j.neurol.2009.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2009.05.018</ArticleId><ArticleId IdType="pubmed">19660777</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Gosset P, Brunaud-Danel V, Lassalle P, Degonne B, Destee A, et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph Lateral Scler. 2009;10(3):175&#x2013;181. doi: 10.1080/17482960802651725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802651725</ArticleId><ArticleId IdType="pubmed">19177252</ArticleId></ArticleIdList></Reference><Reference><Citation>Glas M, Popp B, Angele B, Koedel U, Chahli C, Schmalix WA, et al. A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis. Exp Neurol. 2007;207(2):350&#x2013;356. doi: 10.1016/j.expneurol.2007.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.07.007</ArticleId><ArticleId IdType="pubmed">17716658</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratman AN, Schwindt AE, Malotte KM, Davis GE. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood. 2010;116(22):4720&#x2013;4730. doi: 10.1182/blood-2010-05-286872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-286872</ArticleId><ArticleId IdType="pmc">PMC2996127</ArticleId><ArticleId IdType="pubmed">20739660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771&#x2013;783. doi: 10.1038/nn.4288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4288</ArticleId><ArticleId IdType="pmc">PMC5745011</ArticleId><ArticleId IdType="pubmed">27227366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Korte N, Nortley R, Sethi H, Tang Y, Attwell D. Targeting pericytes for therapeutic approaches to neurological disorders. Acta Neuropathol. 2018;136(4):507&#x2013;523. doi: 10.1007/s00401-018-1893-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1893-0</ArticleId><ArticleId IdType="pmc">PMC6132947</ArticleId><ArticleId IdType="pubmed">30097696</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003;21(3&#x2013;4):109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066375</ArticleId><ArticleId IdType="pubmed">14530574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawata K, Liu CY, Merkel SF, Ramirez SH, Tierney RT, Langford D. Blood biomarkers for brain injury: what are we measuring? Neurosci Biobehav Rev. 2016;68:460&#x2013;473. doi: 10.1016/j.neubiorev.2016.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.05.009</ArticleId><ArticleId IdType="pmc">PMC5003664</ArticleId><ArticleId IdType="pubmed">27181909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapural M, Krizanac-Bengez L, Barnett G, Perl J, Masaryk T, Apollo D, et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 2002;940((1&#x2013;2)):102&#x2013;104. doi: 10.1016/S0006-8993(02)02586-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(02)02586-6</ArticleId><ArticleId IdType="pubmed">12020881</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 2007;10(5):608&#x2013;614. doi: 10.1038/nn1885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1885</ArticleId><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77(4):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664586</ArticleId><ArticleId IdType="pubmed">26663933</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigemoto-Mogami Y, Hoshikawa K, Sato K. Activated microglia disrupt the blood-brain barrier and induce chemokines and cytokines in a rat in vitro model. Front Cell Neurosci. 2018;12:494. doi: 10.3389/fncel.2018.00494.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00494</ArticleId><ArticleId IdType="pmc">PMC6300509</ArticleId><ArticleId IdType="pubmed">30618641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Birngruber T, Sattler W, Kroath T, Ratzer M, Sinner F, et al. Assessment of blood-brain barrier function and the neuroinflammatory response in the rat brain by using cerebral open flow microperfusion (cOFM) PLoS One. 2014;9(5):e98143. doi: 10.1371/journal.pone.0098143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098143</ArticleId><ArticleId IdType="pmc">PMC4031165</ArticleId><ArticleId IdType="pubmed">24852285</ArticleId></ArticleIdList></Reference><Reference><Citation>Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994;125(4):917&#x2013;928. doi: 10.1083/jcb.125.4.917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.125.4.917</ArticleId><ArticleId IdType="pmc">PMC2120083</ArticleId><ArticleId IdType="pubmed">7514607</ArticleId></ArticleIdList></Reference><Reference><Citation>Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun. 2006;347(4):895&#x2013;903. doi: 10.1016/j.bbrc.2006.06.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.06.148</ArticleId><ArticleId IdType="pubmed">16854377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 1999;5(3):181&#x2013;191. doi: 10.1007/BF03402061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03402061</ArticleId><ArticleId IdType="pmc">PMC2230298</ArticleId><ArticleId IdType="pubmed">10404515</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Kim H, Lee HG, Kim BK, Park JY, Kim DY, et al. Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. Oncotarget. 2017;8(35):58974&#x2013;58984. doi: 10.18632/oncotarget.19769.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.19769</ArticleId><ArticleId IdType="pmc">PMC5601707</ArticleId><ArticleId IdType="pubmed">28938611</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neuro-Oncol. 2000;50(1&#x2013;2):121&#x2013;137. doi: 10.1023/A:1006436624862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1006436624862</ArticleId><ArticleId IdType="pubmed">11245272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med. 2007;17(4):140&#x2013;143. doi: 10.1016/j.tcm.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2268985</ArticleId><ArticleId IdType="pubmed">17482097</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y, Lee J, Kwak JY, Noh K, Yim E, Kim HK, et al. Fractalkine induces angiogenic potential in CX3CR1-expressing monocytes. J Leukoc Biol. 2018;103(1):53&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28978662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35(6):518&#x2013;528. doi: 10.1111/neup.12221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12221</ArticleId><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamadera M, Fujimura H, Inoue K, Toyooka K, Mori C, Hirano H, et al. Microvascular disturbance with decreased pericyte coverage is prominent in the ventral horn of patients with amyotrophic lateral sclerosis. Amyotroph Lat Scl Fr. 2015;16(5&#x2013;6):393&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">25740316</ArticleId></ArticleIdList></Reference><Reference><Citation>Swindell WR, Kruse CPS, List EO, Berryman DE, Kopchick JJ. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. J Transl Med. 2019;17(1):170. doi: 10.1186/s12967-019-1909-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-1909-0</ArticleId><ArticleId IdType="pmc">PMC6530130</ArticleId><ArticleId IdType="pubmed">31118040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem. 2004;279(13):12171&#x2013;12180. doi: 10.1074/jbc.M305146200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M305146200</ArticleId><ArticleId IdType="pubmed">14702352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinter MS, Spicer A, Orwoll BO, Alkhouli M, Dvorak CC, Calfee CS, et al. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am J Physiol Lung Cell Mol Physiol. 2016;310(3):L224&#x2013;L231. doi: 10.1152/ajplung.00336.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00336.2015</ArticleId><ArticleId IdType="pmc">PMC5504437</ArticleId><ArticleId IdType="pubmed">26660787</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology. 2005;65(12):1958&#x2013;1960. doi: 10.1212/01.wnl.0000188907.97339.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto M, Bahn E, Wiltfang J, Boekhoff I, Beuche W. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1998;240(3):171&#x2013;173. doi: 10.1016/S0304-3940(97)00947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(97)00947-6</ArticleId><ArticleId IdType="pubmed">9502231</ArticleId></ArticleIdList></Reference><Reference><Citation>Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, et al. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem. 2012;120(5):644&#x2013;659. doi: 10.1111/j.1471-4159.2011.07612.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07612.x</ArticleId><ArticleId IdType="pubmed">22145907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hladky SB, Barrand MA. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids and Barriers of the CNS. 2014;11(1):1&#x2013;32. doi: 10.1186/2045-8118-11-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-8118-11-26</ArticleId><ArticleId IdType="pmc">PMC4326185</ArticleId><ArticleId IdType="pubmed">25678956</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson A, Carlsson L, Gordh T, Lind AL, Thulin M, Kamali-Moghaddam M. The effects of age and gender on plasma levels of 63 cytokines. J Immunol Methods. 2015;425:58&#x2013;61. doi: 10.1016/j.jim.2015.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2015.06.009</ArticleId><ArticleId IdType="pubmed">26080062</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74(12):1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L, Zhang X-D, Miao W-Y, Sun Y-J, Xiong G, Wu Q, et al. PDGFR&#x3b2; cells rapidly relay inflammatory signal from the circulatory system to neurons via chemokine CCL2. Neuron. 2018;100(1):183&#x2013;200. e8. doi: 10.1016/j.neuron.2018.08.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.08.030</ArticleId><ArticleId IdType="pubmed">30269986</ArticleId></ArticleIdList></Reference><Reference><Citation>Manberg A, Skene N, Sanders F, Trusohamn M, Remnestal J, Szczepinska A, et al. Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27(4):640&#x2013;646. doi: 10.1038/s41591-021-01295-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01295-9</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MB, Yang AC, Yousef H, Lee D, Chen W, Schaum N, et al. Brain endothelial cells are exquisite sensors of age-related circulatory cues. Cell Rep. 2020;30(13):4418&#x2013;32 e4. doi: 10.1016/j.celrep.2020.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7292569</ArticleId><ArticleId IdType="pubmed">32234477</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Sanberg PR, Borlongan CV. Potential role of humoral IL-6 cytokine in mediating pro-inflammatory endothelial cell response in amyotrophic lateral sclerosis. Int J Mol Sci. 2018;19(2):423. doi: 10.3390/ijms19020423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19020423</ArticleId><ArticleId IdType="pmc">PMC5855645</ArticleId><ArticleId IdType="pubmed">29385088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999;126(14):3047&#x2013;3055. doi: 10.1242/dev.126.14.3047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.126.14.3047</ArticleId><ArticleId IdType="pubmed">10375497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansson D, Scotter EL, Rustenhoven J, Coppieters N, Smyth LC, Oldfield RL, et al. Interferon-&#x3b3; blocks signalling through PDGFR&#x3b2; in human brain pericytes. J Neuroinflammation. 2016;13(1):249. doi: 10.1186/s12974-016-0722-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0722-4</ArticleId><ArticleId IdType="pmc">PMC5031293</ArticleId><ArticleId IdType="pubmed">27654972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>